TSW
RCPI

Thompson Siegel & Walmsley’s ROCK CREEK PHARMACEUTICALS INC COM STK (DE) RCPI Stock Holding History

Thompson Siegel & Walmsley’s Portfolio RCPI Stock Details RCPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-40
Closed – – 740
2014
Q3 		$0 Hold
40
– – ﹤0.01% 719
2014
Q2 		$1K Buy
+40
New +$694 ﹤0.01% 650

Other funds holding RCPI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GCM
Goldman Capital Management New York $103M AUM 21.37% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thompson Siegel & Walmsley's RCPI Position: Q4 2014 in Review

Thompson Siegel & Walmsley sold out of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) in Q4 2014, closing a stake of 40 shares.

Thompson Siegel & Walmsley first reported a position in RCPI in Q2 2014 and held it in 2 quarters. The position peaked at $1K in Q2 2014. 55 funds tracked by Wall St. Rank hold RCPI as of Q4 2014.

  • Thompson Siegel & Walmsley reported no remaining ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position as of Q4 2014 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 40 ROCK CREEK PHARMACEUTICALS INC COM STK (DE) shares in Q4 2014.
  • Thompson Siegel & Walmsley first reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 2 quarters.
  • Thompson Siegel & Walmsley's ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position peaked at $1K in Q2 2014.
  • 55 funds tracked by Wall St. Rank held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) as of Q4 2014.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2014, filed 9 Feb 2015.